TraceLink customers receive EMVO approval for data submission to EU Hub

6 Jun 2018

Company has developed a standard feature for its customers to execute the EMVO conformance testing successfully.

TraceLink has developed a streamlined program for its 190+ customers to rapidly complete conformance testing and successfully receive European Medicines Verification Organization (EMVO) approval to submit data to the EU Hub - a complex and lengthy process that requires each company to complete EMVO registration and provide a full set of test cases to be executed for conformance with the EU Hub.

TraceLink customers receive EMVO approval for data submission to EU Hub

In just one month, 34 companies have completed their conformance testing with TraceLink’s conformance test kit. Of these, 11 companies have received EMVO approval to submit data to the EU Hub and 14 companies are awaiting review from the EMVO. To achieve final approval, all pharmaceutical companies must now submit a series of transactions to be reviewed by the EMVO, a process that can now take several weeks due to the surge of companies seeking to connect to the EU Hub before the EU Falsified Medicines Directive (FMD) deadline in February 2019. Once the transactions are approved by the EMVO, a pharmaceutical company will receive access to the certificates required for production and data submission to the EU Hub.

To accommodate the more than 190 customers that have selected TraceLink to help meet their EU Falsified Medicines Directive (FMD) requirements, TraceLink has developed a standard feature for its customers to execute the EMVO conformance testing successfully, including specific product functionality and services optimized to help guide customers through the EMVO approval process for connection to the EU Hub. After executing a conformance test, any TraceLink customer using the EU compliance module will receive automatically generated files that are ready to be submitted to the EU Hub for approval.

“The EMVO has stated that there is no longer a formal certification for pharmaceutical companies or solution providers to gain access to the EU Hub, so pharmaceutical companies that are still evaluating solutions should be skeptical of any vendor statements claiming they are ‘EMVO certified.’ The true test is demonstrating how many pharmaceutical companies have actually achieved EMVO approval using a particular solution provider, as this validates correct use of the EU Hub integration APIs,” said Shabbir Dahod, president and CEO of TraceLink. “TraceLink’s history integrating with the EU Hub dates back 2 years, with nearly 650,000 serial numbers submitted to the EU Hub by our customers since 2016. Today, while other solution providers are in the midst of conducting pilot tests and resorting to promotional discount strategies in an attempt to acquire new customers, TraceLink customers are out front, already live in production with serialization and officially approved to submit data to the EU Hub.”

“After working with TraceLink to successfully complete our conformance testing, we have received EMVO approval to begin submitting data to the EU Hub, nearly 10 months ahead of the EU FMD deadline,” said Ortwin Kottwitz, CEO of biosyn. “Gaining EMVO certification with the TraceLink conformance test kit was simple and straightforward, and with TraceLink’s multi-tenant approach, we are well-positioned for continued certification despite any unforeseen changes to our systems in the future.”

Read More

Related news

Allergan to establish R&D presence in Cambridge, Massachusetts

Allergan to establish R&D presence in Cambridge, Massachusetts

10 Jan 2019

The new, strategic presence will allow the company to more easily interact and engage with venture firms and start ups in the area.

Read more 
Expedeon signs supply and license agreement for is Lightning-Link technology

Expedeon signs supply and license agreement for is Lightning-Link technology

9 Jan 2019

The technology will enable Cell Guidance Systems to manufacture TRIFic detection assays on-demand with highly reproducible and scalable results.

Read more 
Lilly to bag Loxo Oncology for $8 billion

Lilly to bag Loxo Oncology for $8 billion

8 Jan 2019

Acquisition will broaden the scope of Lilly's oncology portfolio into precision medicines.

Read more 
Catalent to double its commercial biomanufacturing capacity

Catalent to double its commercial biomanufacturing capacity

7 Jan 2019

The $200-million expansion will support customers’ development programs and commercial launches.

Read more 
BMS and Celgene merge to create premier innovative biopharma company

BMS and Celgene merge to create premier innovative biopharma company

3 Jan 2019

Significantly expands Phase III assets with six expected near-term product launches, representing greater than $15 billion in revenue potential.

Read more 
Cambrex completes acquisition of Avista Pharma Solutions

Cambrex completes acquisition of Avista Pharma Solutions

2 Jan 2019

Acquisition adds a full complement of early-stage development capabilities to Cambrex’s larger scale capabilities for APIs and finished dosage forms.

Read more 
Novartis offers to acquire CellforCure

Novartis offers to acquire CellforCure

1 Jan 2019

Proposed acquisition will expand manufacturing capacity for innovative cell and gene therapies.

Read more 
BMS receives offer from Taisho to purchase UPSA

BMS receives offer from Taisho to purchase UPSA

30 Dec 2018

The potential transaction would position BMS to further refine its portfolio to focus on transformational medicines for patients facing serious diseases.

Read more 
Recipharm to potentially end operations in Ashton-under-Lyne facility

Recipharm to potentially end operations in Ashton-under-Lyne facility

24 Dec 2018

The operation has not been profitable for several years; no likely prospect of it being able to deliver an acceptable return in the medium term.

Read more 
An increased risk of a hard or ‘no deal Brexit?

An increased risk of a hard or ‘no deal Brexit?

24 Dec 2018

A ‘no deal’ Brexit will change and burden how all industries that move materials and goods across borders, including the pharmaceutical and medical device sectors, do business.

Read more